Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04771572
Recruitment Status : Recruiting
First Posted : February 25, 2021
Last Update Posted : June 10, 2022
Sponsor:
Information provided by (Responsible Party):
Newave Pharmaceutical Inc

Brief Summary:
This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.

Condition or disease Intervention/treatment Phase
Non Hodgkin Lymphoma Richter Transformation Multiple Myeloma T-cell-prolymphocytic Leukemia Acute Myeloid Leukemia Acute Lymphocytic Leukemia Myeodysplastic Syndrome Myelodysplastic/Myeloproliferative Neoplasm Myelofibrosis Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Chronic Myelomonocytic Leukemia-2 Myelodysplastic Neoplasm in Blast Phase Drug: LP-118 Phase 1

Detailed Description:

Primary objectives of the study are to assess the safety and tolerability profile, determine the maximum tolerated dose (MTD), and/or the recommended Phase 2 dose (RP2D) of LP-118 administered once daily (QD) as a single agent dosed orally in adult subjects with relapsed/refractory MF, MDS/MPN, CMML-2, MPN-BP, MDS, AML with WBC ≤ 25 × 109 cells/L (Group 1b); relapsed/refractory NHL, RT, MM, T-PLL (Group 1c); relapsed/refractory ALL (Group 1d); relapsed/refractory CLL/SLL, NHL, RT T-PLL patients with intermediated and high tumor lysis risk (Group 2).

Secondary objectives of the study are to evaluate preliminary efficacy regarding the effect of LP-118 on objective response rate (ORR) using disease specific response criteria, progression-free survival (PFS), and duration of response (DOR), and overall survival (OS) n adult subjects with relapsed/refractory MF, MDS/MPN, CMML-2, MPN-BP, MDS, AML with WBC ≤ 25 × 109 cells/L (Group 1b); relapsed/refractory NHL, RT, MM, T-PLL (Group 1c); relapsed/refractory ALL (Group 1d); relapsed/refractory CLL/SLL, NHL, RT T-PLL patients with intermediated and high tumor lysis risk (Group 2).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: The study will start at lower doses (10 mg, 20 mg) and adopt an "accelerated titration" design for these cohorts. Once the safety of the 20 mg dose level is established, we will continue dose escalation using a classic "3+3" design to establish DLT, MTD, and RP2D, starting also with an accelerated step-up dosing schedule.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/1b Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of LP-118 in Subjects With Relapsed or Refractory Hematological Malignancies
Actual Study Start Date : August 23, 2021
Estimated Primary Completion Date : August 1, 2024
Estimated Study Completion Date : August 1, 2024


Arm Intervention/treatment
Experimental: Dose Escalation Phase
Phase 1a dose-escalation will begin with group 1 and proceed until DLT is observed and MTD is established, or until an RP2D is established. Subjects enrolled in the dose cohorts will follow the 3+3 study design, starting with an accelerated step-up dosing schedule (with a starting dose of 20 mg or 50 mg once daily) until they reach the designated target dose (50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg or 600 mg). Once the MTD or RP2D is established for group 1, the phase 1a dose escalation can proceed for group 2. The starting dose level for group 2 will be one dose level below the MTD or RP2D established for group 1.
Drug: LP-118
Evaluate safety and tolerability profile and pharmacokinetics of oral LP-118 in patients on a once daily schedule.

Experimental: Dose Expansion Phase
Additional subjects will be recruited to further explore the safety, tolerability, PK, and efficacy in specific subject subgroups. One or more RP2D may be explored. Definition of these cohorts will be accomplished by protocol amendment, and in light of emerging data from Phase 1a.
Drug: LP-118
Evaluate safety and tolerability profile and pharmacokinetics of oral LP-118 in patients on a once daily schedule.




Primary Outcome Measures :
  1. Maximum Tolerated Dose (MTD) [ Time Frame: At the end of cycle 1 (each cycle is 28 days) ]
    If 2 out of 6 subjects in an expanded cohort experience a DLT then this dose is considered the MTD.

  2. Recommended Phase 2 Dose (RP2D) or Optimal Biological Dose (OBD) [ Time Frame: At the end of cycle 1 (each cycle is 28 days) ]
    The RP2D pr OBD may be as high as the MTD or a lower dose and will be selected in discussion with the Investigators and the Sponsor based on longer term safety data, preliminary efficacy, and PK data. OBD is defined as the lowest dose providing the highest rate of efficacy while being safely administered.

  3. Pharmacokinetic (PK) profile of LP-118: Maximum Plasma Concentration (Cmax) [ Time Frame: At Cycle 0 Day 1, Cycle 1 Day 1, Cycle 1 Day 15, Cycle 1 Day 16, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1, Cycle 7 Day 1, Cycle 8 Day 1, Cycle 9 Day 1 (28-day cycles)) ]
  4. Pharmacokinetic (PK) profile of LP-118: Area Under the Curve (AUC) of LP-118 [ Time Frame: At Cycle 0 Day 1, Cycle 1 Day 1, Cycle 1 Day 15, Cycle 1 Day 16, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1, Cycle 7 Day 1, Cycle 8 Day 1, Cycle 9 Day 1 (28-day cycles) ]
  5. Pharmacokinetic (PK) profile of LP-118: Time at Maximum Concentration (Tmax) of LP-118 [ Time Frame: At Cycle 0 Day 1, Cycle 1 Day 1, Cycle 1 Day 15, Cycle 1 Day 16, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1, Cycle 7 Day 1, Cycle 8 Day 1, Cycle 9 Day 1 (28-day cycles) ]

Secondary Outcome Measures :
  1. Progression-Free Survival (PFS) [ Time Frame: Approximately 36 cycles (each cycle has 28 days) ]
    The number of days from the date the subject started study drug to the date the subject experiences an event of disease progression (radiographic or clinical), or to the date of death if disease progression is not reached.

  2. Duration of Response (DOR) [ Time Frame: Approximately 36 cycles (each cycle is 28 days) ]
    The number of days from the date the subject started study drug to the date of the subject's death due to any cause.

  3. Overall Survival (OS) [ Time Frame: Approximately 36 cycles (each cycle is 28 days) ]
    The number of days from the date the subject started study drug to the date of the subject's death due to any cause.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female subjects, ≥ 18 years of age at the time of Screening with the following exception as outlined below:

    o For T cell and B cell ALL subjects with age between 13 - 18 years, their body weight shall be ≥ 40 kg (for Phase 1b only).

  • Eligible subject must have an advanced hematologic malignancy including:

Group 1:

Group 1a

- Relapsed or refractory low risk tumor lysis CLL/SLL subjects (ALC < 25 x 109 /cells/L and all lymph nodes < 5 cm) who have slowly progressed on irreversible BTK inhibitors while on treatment with these agents, and received at least two prior therapies;

Group 1b

  • Morphologically confirmed diagnosis of MF in accordance with the WHO 2016 revised criteria, that is relapsed, intolerant, and/or refractory and that, in the opinion of the Investigator, subjects who have no available therapies known to provide clinical benefits;
  • Morphologically confirmed diagnosis of MDS/MPN, excluding juvenile myelomonocytic leukemia (JMML), in accordance with WHO 2016 revised criteria, that is relapsed and/or refractory and that, in the opinion of the Investigator, subjects who have no available therapies known to provide clinical benefits;

    • Chronic myelomonocytic leukemia (CMML) with 9% blasts;
    • Or atypical chronic myeloid leukemia (aCML) with Hgb > 10g/dL, WBC count < 50 x 109 cells/L, <10% immature circulating cells;
    • Or MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) with Hgb > 10g/dL;
    • Or myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-UC)
  • CMML-2 with 10-19% blasts as defined by WHO 2016 revised criteria that is relapsed and/or refractory to prior HMA therapy;
  • Relapsed and/or refractory MPN-BP as defined by WHO 2016 revised criteria that is transformed MPN with >20% myeloid blasts in the peripheral blood or bone marrow, in the opinion of the Investigator, subjects who have no available therapies known to provide clinical benefits;
  • MDS subjects with refractory anemia with excess blasts (MDS-EB; subtype MDS-EB-1 or MDS-EB-2) as defined by WHO 2016 revised criteria and/or MDS with high- or very high-risk (risk score > 4.5) per the Revised International Prognostic Scoring System (IPSS-R, refer to Appendix 11; Section 15.13) who have no available therapies known to provide clinical benefit;
  • Relapsed or refractory AML subjects (including de novo AML, secondary AML evolving from MDS or MPN or other antecedent hematologic disorder, and therapy-related AML) as defined by WHO 2016 revised criteria, subjects who have no available therapies known to provide clinical benefits; subjects with prior BCL-2 inhibitor therapy are permitted. WBC needs to be ≤ 25 × 109 cells/L at the time of initiating investigational therapy (hydroxyurea is allowed to control WBC prior to and during therapy).

Group 1c

  • Relapsed or refractory low risk tumor lysis NHL (NHL histologies [MZL, FL, WM, DLBCL, ATLL, PTCL, AITL, ALCL, MCL] are to be included per the 2016 World Health Organization [WHO] criteria) subjects, must have histologically documented diagnosis of a non-Hodgkin lymphoma as defined in the WHO classification scheme. Subjects have received at least 2 prior therapies and have no available therapies known to provide clinical benefit; For subjects with indolent NHL (Grade 1~3a FL, MZL) who have received two prior systemic therapies and have relapsed or progressed according to 2014 Lugano;
  • Low risk tumor lysis transformed follicular, MZL, WM (to large cell or aggressive lymphoma) subjects who must have received at least one prior systemic therapy for the transformed lymphoma (unless combination chemotherapy is not appropriate);
  • Low risk tumor lysis Richter transformation (RT): previously treated CLL and biopsy-proven Richter transformation with DLBCL histology after receiving at least one regimen for RT;
  • Relapsed or refractory multiple myeloma (MM) subjects who have received a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 and have no treatment options available known to provide clinical benefit;
  • Low risk tumor lysis T-cell prolymphocytic leukemia (T-PLL) subjects who have received one therapy for this and are relapsed or refractory;

Group 1d

  • Relapsed or refractory ALL with dexamethasone run-in [5 days, dexamethasone 10mg/m2 (divided BID)];
  • Or r/r ALL in remission but with detectable MRD (MRD +) by any detection method per institution standard of practice;
  • IT chemo (per institutional SOC) is permitted prior to LP-118 C1D1 dosing, and then concomitantly on treatment if in best interest of the subject;
  • Relapsed or refractory ALL subjects with B cell phenotype who have received at least two prior therapeutic regimens (such as multi-agent chemotherapy and/or tyrosine kinase inhibitors including bosutinib, dasatinib, imatinib, nilotinib or ponatinib) and failed, or are currently ineligible/intolerant for CD19-based target therapy (e.g. Blinatumomab); Relapsed or refractory ALL subjects with T cell phenotype who have received at least one prior therapy and failed.

Group 2

  • Relapsed or refractory intermediate and high risk tumor lysis CLL/SLL subjects who have received at least two prior therapies;
  • Relapsed or refractory intermediate and high risk tumor lysis NHL (NHL histologies [MZL, FL, WM, DLBCL, ATLL, PTCL, AITL, ALCL, MCL] are to be included per the 2016 World Health Organization [WHO] criteria) subjects, must have histologically documented diagnosis of a non-Hodgkin lymphoma as defined in the WHO classification scheme. Subjects have received at least 2 prior therapies and have no available therapies known to provide clinical benefit; For subjects with indolent NHL (Grade 1~3a FL, MZL) who have received two prior systemic therapies and have relapsed or progressed according to 2014 Lugano;
  • Intermediate and high risk tumor lysis transformed follicular, MZL, WM (to large cell or aggressive lymphoma) subjects who must have received at least one prior systemic therapy for the transformed lymphoma (unless combination chemotherapy is not appropriate);
  • Intermediate and high risk tumor lysis Richter transformation (RT): previously treated CLL and biopsy-proven Richter transformation with DLBCL histology after receiving at least one regimen for RT;
  • Intermediate and high risk tumor lysis T-cell prolymphocytic leukemia (T-PLL) subjects who have received one therapy for this and are relapsed or refractory;
  • For Group 1d ALL subjects only, white blood cell (WBC) count ≤ 25 × 109 cells/L at the time of enrollment (glucocorticoids or hydroxyurea is permitted to control WBC count prior to and during therapy).
  • Adequate cardiac function defined as shortening fraction of ≥ 40% by 2D echocardiogram without Doppler.
  • Subject must have adequate bone marrow (independent of growth factor support), coagulation, renal, and hepatic function, per laboratory reference ranges at Screening as follows:

    • Bone marrow criteria: Group 1 (r/r low risk tumor lysis CLL/SLL (ALC < 25 x 109 cells/L and all lymph nodes < 5 cm), NHL, RT, MM, T-PLL):

      1. Absolute Neutrophil Count (ANC) ≥ 1 x 109/L (An exception is for subjects with an ANC<1 x 109/L and bone marrow heavily infiltrated with underlying disease)
      2. Platelets ≥ 50 x 109/L on day of screening (entry platelet count must be independent of transfusion with 14 days of screening);
    • Hemostasis criteria: Activated partial thromboplastin time (APPT) and prothrombin time (PT) ≤ 1.5 × the upper limit of normal (ULN);
    • Renal function criteria: Serum creatinine ≤ ULN (per local institution reference range) or Calculated creatinine clearance (Cr Cl) ≥ 60 mL/min using 24-hour CrCl OR by Cockcroft-Gault formula using actual body weight.
    • Hepatic function criteria: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × ULN; bilirubin ≤ 1.5 × ULN (except subjects with Gilbert's Syndrome, who may have a bilirubin > 1.5 × ULN, per discussion between the Investigator and the Medical Monitor).

Exclusion Criteria:

A subject will not be eligible for study participation if he/she meets any of the following criteria.

  • Subjects who have undergone autologous/allogeneic hematopoietic stem cell transplantation (HSCT) therapy within 60 days of the first dose of LP-118, or subjects on immunosuppressive therapy post-HSCT at the time of Screening, or currently with clinically significant graft-versus-host disease (GVHD) as per treating physician (Subjects in relapse after allogeneic transplantation must be off treatment with systemic immunosuppressive agents for at least 4 weeks. The use of topical steroids and/or up to 20 mg/day prednisone or equivalent systemic steroids for ongoing GVHD is permitted).
  • Subject has a history of other malignancies within past 12 months that are active and could result in competing risks. These cases shall be discussed with the Medical Monitor with exception below

    • Subject with breast cancer or prostate cancer on endocrine therapy with stable disease;
    • Continuation of maintenance therapy in patients with adequately treated malignancy;
    • Adequately treated in situ carcinoma of the cervix uteri;
    • Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;
    • Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent.
    • Cancer with expected survival of 2 years or more or that will not confound evaluation of LP-118 treatment
  • Subject has received any of the following therapies within 14 days or 5 half-lives (whichever is shorter) prior to the first dose of LP-118, or has not recovered to ≤ Grade 2 clinically significant AEs of the previous therapy (excluding neuropathy):

    • Any anti-neoplastic therapy including chemotherapy, hormonal therapy, radiotherapy, biologic or immunotherapy, targeted small molecule agents, etc. (corticosteroid therapy < 20 mg/day prednisone equivalent and hydroxyurea cytoreduction therapy according to institutional guidelines to treat disease associated symptoms are permitted);

      • For MF subjects who come off JAK2 antagonists, allow washout for 2 days as these subjects progress quickly after treatment discontinuation and remain eligible (steroids may be given during these two days to allow disease control).
      • Subjects in need of immediate cytoreduction should be excluded.
    • Any investigational therapy.
    • Live vaccines
  • Subject has received the following medications, therapies or natural products within 7 days prior to the first dose of LP-118:

    • Cytochrome P450, family 3, subfamily A (CYP3A) strong inhibitors (itraconazole, etc) or inducers (phenytoin, rifampin, etc);
    • Inhibitors of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP).
    • There is a 28 day washout period required for subjects who have had prior CAR-T treatment if there is no evidence of cytokine release syndrome (CRS) or other adverse events related to the CAR-T treatment, per discussion with the Medical Monitor.
  • Subject has baseline prolongation of the heart rate-corrected QT (QTcF) interval ≥ 480 ms (calculated per Fridericia's formula [QTcF = QT/RR(1/3)]) ), a cardiovascular disability status of New York Heart Association Class ≥ 2 or associated other significant screening ECG or ultrasonic cardiogram abnormalities, per Investigator's judgement.
  • Subject has significant a history of congenital long QT syndrome or Torsades de Pointes, uncontrolled or symptomatic arrhythmias, congestive heart failure, myocardial infarction, stroke or intracranial hemorrhage within 6 months prior to the first dose of LP-118.
  • Subject exhibits evidence of other clinically significant uncontrolled condition(s) including, but not limited to:

    • Uncontrolled active systemic infection (bacterial, fungal, viral);
    • Known poorly controlled of human immunodeficiency virus (HIV) or active hepatitis B or C infection (active hepatitis B defined as HBsAg positive, or HBcAb positive with detectable HBV DNA load; active hepatitis C defined as HCV antibody positive with HCV RNA positive);
    • Unexplained fever > 38.5°C within 7 days prior to the first dose of study drug administration (at the discretion of the Investigator, if the fever is considered attributed to the subject's malignancy or an explained infection may be enrolled).
  • Subjects with known and active central nervous system (CNS) involvement at Screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04771572


Contacts
Layout table for location contacts
Contact: Anna Chen, MD (925) 989 4601 yu@newavepharma.com
Contact: Stephen Anthony, DO s.anthony@newavepharma.com

Locations
Layout table for location information
United States, Illinois
University of Chicago Recruiting
Chicago, Illinois, United States, 60637
United States, North Carolina
University of North Carolina Not yet recruiting
Chapel Hill, North Carolina, United States, 27514
United States, Ohio
University of Cincinnati Recruiting
Cincinnati, Ohio, United States, 45229
Sponsors and Collaborators
Newave Pharmaceutical Inc
Layout table for additonal information
Responsible Party: Newave Pharmaceutical Inc
ClinicalTrials.gov Identifier: NCT04771572    
Other Study ID Numbers: LP-118-US-I01
First Posted: February 25, 2021    Key Record Dates
Last Update Posted: June 10, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Leukemia
Neoplasms
Multiple Myeloma
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Myelomonocytic, Chronic
Leukemia, Myelomonocytic, Juvenile
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Prolymphocytic
Blast Crisis
Leukemia, Prolymphocytic, T-Cell
Preleukemia
Myeloproliferative Disorders
Myelodysplastic-Myeloproliferative Diseases
Myelodysplastic Syndromes
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, Myeloid
Neoplasms, Plasma Cell
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders